Vit D and asymptomatic PSA Nov 2009
BJU Int. 2009 Nov;104(9):1204-7. Epub 2009 Apr 24.
The promiscuous receptor.
Newsom-Davis TE, Kenny LM, Ngan S, King J, Waxman J.

Department of Oncology, Imperial College London, Hammersmith Hospital, London, UK.

OBJECTIVE: To determine the effectiveness of vitamin D therapy in patients with asymptomatic, prostate-specific antigen (PSA)-progression of prostate cancer. PATIENTS AND METHODS: Twenty-six patients with locally advanced or metastatic prostate cancer were treated with vitamin D. Vitamin D therapy was discontinued on disease progression as assessed by symptoms or serum PSA increase. The response to therapy was judged from changes in PSA level from the pretreatment baseline to 3 months after starting vitamin D therapy. RESULTS: Of the 26 patients, five (20%) responded to vitamin D; the mean (range) reduction in PSA level was 45.3 (15.9-95.1)%, and mean duration of response was 4-5 months. Patients in whom the PSA level was stabilized, but not reduced, after vitamin D treatment had a duration of response of up to 36 months. Treatment was well tolerated and was not associated with elevation of serum calcium levels. There was no significant correlation between response to therapy and stage of disease, Gleason grade, previous treatments or PSA level at diagnosis or initiation of vitamin D therapy. CONCLUSION: Vitamin D therapy is an effective and well tolerated treatment for patients with asymptomatic progressive prostate cancer, and is a useful addition to the therapeutic options.

PMID: 19426197 [PubMed - indexed for MEDLINE]